Immune checkpoint inhibitors (ICI), such as anti-programmed death-1 (PD-1) and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies, have shown widespread effectiveness in treating many cancers particularly malignant melanoma. This evidence concerns the gene CTLA4 and melanoma.